Feed Preview

Antisense Oligonucleotides: ND

Antisense Oligonucleotides: ND diagram by Robinson R, Wikimedia
Robinson R, Wikimedia

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Top 20 most recent papers
Science

Antisense oligonucleotides for neurodegeneration

ScienceMarch 29, 2020
Blair R Leavitt, Sarah J Tabrizi
63
Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics of current and emerging treatments for hypercholesterolemia

Expert Opinion on Drug Metabolism & ToxicologyApril 1, 2020
Brian TomlinsonChristopher Wai Kei Lam
Nature Reviews. Neurology

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Nature Reviews. NeurologyMarch 24, 2020
Francesco PanzaBruno P Imbimbo
25
Cardiovascular Research

Non-coding RNA therapeutics for cardiac regeneration

Cardiovascular ResearchMarch 28, 2020
Luca BragaMauro Giacca
2
Cellular and Molecular Neurobiology

Bradykinin Receptors Play a Critical Role in the Chronic Post-ischaemia Pain Model

Cellular and Molecular NeurobiologyMarch 31, 2020
Elaine C D GonçalvesRafael C Dutra
Molecular Therapy. Nucleic Acids

An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement

Molecular Therapy. Nucleic AcidsMarch 13, 2020
Shane G PoplawskiCeleste B Greer
2
Bioorganic & Medicinal Chemistry Letters

Modulation of DNA and RNA by PNA

Bioorganic & Medicinal Chemistry LettersMarch 10, 2020
Penthip Muangkaew, Tirayut Vilaivan
1
Journal of the American Chemical Society

Origins of the increased affinity of phosphorothioate-modified therapeutic nucleic acids for proteins

Journal of the American Chemical SocietyMarch 24, 2020
Malwina Hyjek-SkładanowskaMarcin Nowotny
Therapeutic Advances in Neurological Disorders

Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen

Therapeutic Advances in Neurological DisordersMarch 18, 2020
Elisabeth JochmannJulian Grosskreutz
Nucleic Acid Therapeutics

Delivery of Antisense Oligonucleotides to the Cornea

Nucleic Acid TherapeuticsMarch 24, 2020
Viet Q ChauV Vinod Mootha
American Journal of Respiratory Cell and Molecular Biology

Antisense Oligonucleotides Targeting Jagged 1 Reduce House Dust Mite-Induced Goblet Cell Metaplasia in the Adult Murine Lung

American Journal of Respiratory Cell and Molecular BiologyMarch 17, 2020
Michele CarrerTamar R Grossman
3
BMC Veterinary Research

Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma

BMC Veterinary ResearchMarch 27, 2020
Douglas H ThammKristen M Weishaar
3

See more papers from this feed

Related Feeds

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

© 2020 Meta ULC. All rights reserved
/feed-previews/antisense-oligonucleotides-nd/505ac79a-0f9c-47df-b5f7-64869436e8f5